Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Xiamen Amoytop Biotech Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 14, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	31,673	29,847	21,296	15,837	11,911	13,872
Market Cap Growth	-2.57%	40.15%	34.47%	32.96%	-14.13%	-
Enterprise Value	30,989	29,272	20,670	15,360	11,446	13,419
Last Close Price	77.86	72.76	51.54	38.13	28.57	33.22
PE Ratio	33.70	36.06	38.34	55.18	65.73	119.00
Forward PE	23.01	28.12	28.12	28.12	28.12	64.34
PS Ratio	9.48	10.60	10.14	10.37	10.52	17.47
PB Ratio	10.53	11.69	11.35	11.25	10.26	13.87
P/TBV Ratio	12.34	12.53	12.64	12.32	11.74	16.75
P/FCF Ratio	83.32	166.48	95.23	109.98	271.61	-
P/OCF Ratio	51.95	69.31	41.59	43.61	50.73	149.79
EV/Sales Ratio	9.27	10.39	9.84	10.06	10.11	16.90
EV/EBITDA Ratio	27.96	29.58	28.98	38.09	43.97	81.31
EV/EBIT Ratio	29.85	31.46	31.32	42.66	51.64	105.77
EV/FCF Ratio	81.52	163.28	92.42	106.67	260.99	-
Debt / Equity Ratio	0.05	0.00	0.00	0.01	0.02	0.02
Debt / EBITDA Ratio	0.13	0.01	0.01	0.02	0.10	0.11
Debt / FCF Ratio	0.37	0.05	0.04	0.07	0.57	-
Asset Turnover	1.03	1.04	1.02	0.96	0.87	0.80
Inventory Turnover	0.76	0.82	0.89	1.39	1.18	1.01
Quick Ratio	3.04	3.55	2.80	3.04	4.01	5.76
Current Ratio	3.84	4.34	3.32	3.57	4.71	6.72
Return on Equity (ROE)	35.63%	37.37%	33.83%	22.35%	16.77%	14.91%
Return on Assets (ROA)	20.06%	21.51%	19.99%	14.09%	10.59%	8.00%
Return on Capital (ROIC)	23.92%	26.15%	24.98%	17.29%	12.56%	9.65%
Return on Capital Employed (ROCE)	32.40%	35.40%	33.80%	24.00%	17.80%	11.80%
Earnings Yield	2.97%	2.77%	2.61%	1.81%	1.52%	0.84%
FCF Yield	1.20%	0.60%	1.05%	0.91%	0.37%	-0.19%
Dividend Yield	0.80%	0.85%	0.80%	0.56%	0.35%	0.15%
Payout Ratio	26.86%	20.15%	15.60%	14.17%	11.41%	10.91%
Buyback Yield / Dilution	0.07%	-0.56%	-0.29%	-0.39%	-0.18%	-12.54%
Total Shareholder Return	0.86%	0.30%	0.50%	0.17%	0.18%	-12.38%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.